New York Times, March 22, 2016
See more GHRI in the media.
April 19, 2016—Research at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression.
Read it in News and Events.
With $10 million from NIMH, GHRI is leading a multi-site study to ensure safe prescribing of antipsychotic drugs for youth with behavioral disorders.
Thursday, June 2, 2016
Monday, June 27, 2016
Seattle Sheraton Hotel
Are you a member of the news media interested in learning more about our research? We’re here to help. Please visit our For the Media page for more resources—and contact us.